AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26766797 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic lithotripter
Number of subjects: 77
Study 24986217 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) intervention
Number of subjects: 14099
Study 24986217 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14099
Study 22569025 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-fentanyl
Number of subjects: 411
Study 22569025 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-remifentanil
Number of subjects: 411
Study 22569025 — intervention group
Group type: COMPARATOR
Intervention: Propofol-remifentanil
Number of subjects: 411
Study 22569025 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil groups
Number of subjects: 411
Study 19171291 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 0
Study 19171291 — intervention group
Group type: COMPARATOR
Intervention: Control group (education)
Number of subjects: 0
Study 17991258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.3 microg.kg(‐1)
Number of subjects: 510
Study 17991258 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 3 microg.kg(‐1)
Number of subjects: 510
Study 17991258 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 510
Study 17991258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 510
Study 15718317 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy/15 fractions during 3 weeks
Number of subjects: 625
Study 15718317 — intervention group
Group type: COMPARATOR
Intervention: 20 Gy/10 fractions over 2 weeks
Number of subjects: 625
Study 12010273 — intervention group
Group type: EXPERIMENTAL
Intervention: Insyte AutoGuard
Number of subjects: 300
Study 12010273 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective Acuvance
Number of subjects: 300
Study 12010273 — intervention group
Group type: COMPARATOR
Intervention: Conventional catheter needle (Insyte)
Number of subjects: 300
Study 10464781 — intervention group
Group type: COMPARATOR
Intervention: SF-bread
Number of subjects: 18
Study 7818111 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4 micrograms/kg IV
Number of subjects: 48
Study 7818111 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 6 micrograms/kg IV
Number of subjects: 48
Study 7818111 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms/kg IV
Number of subjects: 48
Study 7818111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 2112187 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐ORS + SF
Number of subjects: 200
Study 2112187 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐ORS + RF
Number of subjects: 200
Study 2112187 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐ORS + rice
Number of subjects: 200
Study 2112187 — intervention group
Group type: COMPARATOR
Intervention: G‐ORS + SF
Number of subjects: 200
Study 465279 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 4%
Number of subjects: 14
Study 465279 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline 1%
Number of subjects: 14
Study 465279 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with atenolol and adrenaline
Number of subjects: 14
Study 465279 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 14
Study 30590556 — intervention group
Group type: EXPERIMENTAL
Intervention: Health behaviours perceived as generating enduring and fundamental benefits
Number of subjects: 242
Study 30590556 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs with enduring benefits
Number of subjects: 242
Study 30590556 — intervention group
Group type: EXPERIMENTAL
Intervention: Future clarity measure
Number of subjects: 242
Study 31550810 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored quadruple therapy based on clarithromycin sensitivity
Number of subjects: 0
Study 31550810 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving clarithromycin quadruple therapy (PPI, amoxicillin, clarithromycin, bismuth)
Number of subjects: 0
Study 28755406 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg apple polyphenols for 8 weeks
Number of subjects: 62
Study 28755406 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 62
Study 26451235 — intervention group
Group type: EXPERIMENTAL
Intervention: Red meat consumption
Number of subjects: 66
Study 26451235 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperferritinemia
Number of subjects: 66
Study 26451235 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron intake
Number of subjects: 66
Study 26451235 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome risk factors
Number of subjects: 66
Study 23557482 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention consisting of up to six face-to-face counseling sessions with a trained practice nurse, followed by three-monthly sessions by phone.
Number of subjects: 622
Study 23557482 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 622
Study 23557482 — intervention group
Group type: COMPARATOR
Intervention: Control group (health brochures)
Number of subjects: 622
Study 21538030 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg daily for 8 weeks
Number of subjects: 175
Study 21538030 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 175
Study 20104156 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteochondral autologous transplantation (OAT)
Number of subjects: 50
Study 20104156 — intervention group
Group type: COMPARATOR
Intervention: Microfracture (MF)
Number of subjects: 50
Study 20104156 — intervention group
Group type: EXPERIMENTAL
Intervention: OAT
Number of subjects: 50
Study 20104156 — intervention group
Group type: COMPARATOR
Intervention: MF
Number of subjects: 50
Study 17328057 — intervention group
Group type: EXPERIMENTAL
Intervention: Onercept 100 mg
Number of subjects: 127
Study 15316583 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei fermented milk (108 ‐ 1010/g), 3 cups per day for 8 weeks
Number of subjects: 45
Study 15316583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 11952581 — intervention group
Group type: EXPERIMENTAL
Intervention: Day surgery
Number of subjects: 100
Study 9481553 — intervention group
Group type: EXPERIMENTAL
Intervention: Day case surgery
Number of subjects: 194
Study 9481553 — intervention group
Group type: COMPARATOR
Intervention: In-patient admission
Number of subjects: 194
Study 9481553 — intervention group
Group type: COMPARATOR
Intervention: Non-randomised in-patient group
Number of subjects: 194
Study 7612535 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g four times daily on days 1 to 4 for two cycles)
Number of subjects: 103
Study 7612535 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone (5 mg twice a day on days 19 and 26 for two cycles)
Number of subjects: 103
Study 7612535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 2653386 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA and 5 HTP in small doses
Number of subjects: 17
Study 2653386 — intervention group
Group type: COMPARATOR
Intervention: R-tetrahydrobiopterin (R-THBP)
Number of subjects: 17
Study 2653386 — intervention group
Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 17
Study 792398 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (5-HTP)
Number of subjects: 1
Study 792398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 29549588 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel (A0.3/BPO2.5)
Number of subjects: 67
Study 29549588 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 67
Study 27028749 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg
Number of subjects: 0
Study 27028749 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium (TIO) 18 mcg + Indacaterol (IND) 150 mcg
Number of subjects: 0
Study 27028749 — intervention group
Group type: COMPARATOR
Intervention: Tiotropinium (TIO) 18 mcg + Indacaterol (IND) 150 mcg
Number of subjects: 0
Study 24674732 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of Evicel (fibrin sealant)
Number of subjects: 62
Study 24674732 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin sealant)
Number of subjects: 62
Study 22331237 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant NP (vinorelbine and cisplatin) and Rh-endostatin
Number of subjects: 72
Study 22331237 — intervention group
Group type: COMPARATOR
Intervention: Single NP (vinorelbine and cisplatin)
Number of subjects: 72
Study 22331237 — intervention group
Group type: EXPERIMENTAL
Intervention: Rh-endostatin followed by NP
Number of subjects: 72
Study 22331237 — intervention group
Group type: EXPERIMENTAL
Intervention: Rh-endostatin
Number of subjects: 72
Study 22331237 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (concomitant NP and Rh-endostatin)
Number of subjects: 72
Study 22331237 — intervention group
Group type: EXPERIMENTAL
Intervention: Rh-endostatin combined with chemotherapy
Number of subjects: 72
Study 20798023 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity programme (9 weeks, 60 minutes per session)
Number of subjects: 481
Study 20798023 — intervention group
Group type: COMPARATOR
Intervention: Health behaviour education sessions (control group)
Number of subjects: 481
Study 20798023 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity programme (9 weeks)
Number of subjects: 481
Study 17356003 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 180
Study 17356003 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (RTE)
Number of subjects: 180
Study 17356003 — intervention group
Group type: COMPARATOR
Intervention: No intervention (C)
Number of subjects: 180
Study 16381266 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.15%; 15 mg) + Fentanyl (0.0002%; 2 microg/ml) + Epinephrine (1.7 microg/ml; 1:600,000)
Number of subjects: 50
Study 16381266 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (0.15%; 15 mg) + Fentanyl (0.0002%; 2 microg/ml)
Number of subjects: 50
Study 11912423 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient/clinic based setting
Number of subjects: 25
Study 11912423 — intervention group
Group type: COMPARATOR
Intervention: Inpatient/operative setting
Number of subjects: 25
Study 9798343 — intervention group
Group type: COMPARATOR
Intervention: HLA-Cw1
Number of subjects: 26
Study 9798343 — intervention group
Group type: COMPARATOR
Intervention: HLA-B46
Number of subjects: 26
Study 9798343 — intervention group
Group type: COMPARATOR
Intervention: HLA-DQB1*0303
Number of subjects: 26
Study 8561257 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) 300 mg weekly
Number of subjects: 0
Study 8561257 — intervention group
Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 0
Study 8561257 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 0
Study 2539655 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide 300 mg/m2 for two days
Number of subjects: 103
Study 2539655 — intervention group
Group type: COMPARATOR
Intervention: Combination of vincristine 1 mg/m2, doxorubicin 50 mg/m2, and cyclophosphamide 1000 mg/m2 (VAC)
Number of subjects: 103
Study 2539655 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide
Number of subjects: 103
Study 2539655 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy (VAC)
Number of subjects: 103
Study 71973 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg flurbiprofen daily for 2 weeks
Number of subjects: 30
Study 71973 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg indomethacin daily for 2 weeks
Number of subjects: 30
Study 71973 — intervention group
Group type: COMPARATOR
Intervention: Placebo washout period
Number of subjects: 30
Study 30745014 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (in-hospital dose)
Number of subjects: 430
Study 30745014 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide utilisation relative to baseline
Number of subjects: 430
Study 30745014 — intervention group
Group type: COMPARATOR
Intervention: Systolic Blood Pressure (SBP)
Number of subjects: 430
Study 31290727 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 monoclonal antibody-conjugated miR-130a/oxaliplatin-loaded immunoliposomes (PD-miOXNP)
Number of subjects: 0
Study 27792019 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented electromyography-triggered stimulation for 30 minutes, five times a week for four weeks
Number of subjects: 20
Study 27792019 — intervention group
Group type: COMPARATOR
Intervention: Cyclic functional electrical stimulation for 30 minutes, five times a week for four weeks
Number of subjects: 20
Study 25731736 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 34
Study 25731736 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study 23011843 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (300 mL of 0.5% bupivacaine)
Number of subjects: 150
Study 23011843 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (300 mL of 0.9% normal saline solution)
Number of subjects: 150
Study 21742399 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (group T)
Number of subjects: 81
Study 21742399 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (group A)
Number of subjects: 81
Study 18081859 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix protein derivative (EMD) + low-level laser therapy (LLLT)
Number of subjects: 22
Study 18081859 — intervention group
Group type: COMPARATOR
Intervention: Enamel matrix protein derivative (EMD)
Number of subjects: 22
Study 16977952 — intervention group
Group type: EXPERIMENTAL
Intervention: Propex apex locator
Number of subjects: 100
Study 16977952 — intervention group
Group type: EXPERIMENTAL
Intervention: Raypex-4 apex locator
Number of subjects: 100
Study 12711730 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners in Caregiving intervention (communication and conflict resolution training)
Number of subjects: 1587
Study 11084267 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmechanical trephination (NMT)
Number of subjects: 96
Study 11084267 — intervention group
Group type: COMPARATOR
Intervention: Mechanical trephination (MT)
Number of subjects: 96
Study 9366727 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist community rehabilitation for up to 3 months after randomisation
Number of subjects: 331
Study 9366727 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospital and community care
Number of subjects: 331
Study 10136097 — intervention group
Group type: EXPERIMENTAL
Intervention: Appointment reminder postcards for 2 weeks
Number of subjects: 10
Study 10136097 — intervention group
Group type: EXPERIMENTAL
Intervention: Appointment reminder phone calls for 2 weeks
Number of subjects: 10
Study 10136097 — intervention group
Group type: COMPARATOR
Intervention: No intervention for 2 weeks
Number of subjects: 10
Study 3110307 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune serum gamma globulin (ISG) 5 or 10 ml
Number of subjects: 107803
Study 3110307 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune serum gamma globulin (ISG) 2 ml
Number of subjects: 107803
Study 3110307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107803
Study 29318418 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (US) at continuous mode, 1-MHz frequency, and 1.5-W/cm2 intensity for 10 sessions
Number of subjects: 32
Study 29318418 — intervention group
Group type: COMPARATOR
Intervention: Control group (unaffected cervical NR)
Number of subjects: 32
Study 24432969 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game performance
Number of subjects: 29
Study 24432969 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgical skills
Number of subjects: 29
Study 24432969 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic skills
Number of subjects: 29
Study 22609300 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise training (3 times a week, 60 minutes per session for 8 weeks)
Number of subjects: 32
Study 22609300 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 32
Study 20423986 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (50 microg)
Number of subjects: 20
Study 20423986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18698280 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 81
Study 18698280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 15924594 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily (continuous)
Number of subjects: 2156
Study 15924594 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg on-demand
Number of subjects: 2156
Study 15924594 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice-daily (continuous)
Number of subjects: 2156
Study 15924594 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily (during the 4-week symptom control phase)
Number of subjects: 2156
Study 12562742 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 151
Study 12562742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 12562742 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (post hoc analysis excluding carbamazepine-treated patients)
Number of subjects: 151
Study 12562742 — intervention group
Group type: COMPARATOR
Intervention: Placebo (post hoc analysis excluding carbamazepine-treated patients)
Number of subjects: 151
Study 10650568 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (2 g/tid p.o. before meals)
Number of subjects: 120
Study 10650568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 10650568 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 120
Study 7745965 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatectomy
Number of subjects: 0
Study 7745965 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hepatectomy)
Number of subjects: 0
Study 7745965 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatectomy Group A (AKBR maintained at 0.7 or more)
Number of subjects: 0
Study 7745965 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatectomy Group B (AKBR decreased to below 0.7)
Number of subjects: 0
Study 1967882 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% hydrogen peroxide in a stabilized lipid cream applied for 2 min before UVA exposure
Number of subjects: 0
Study 1967882 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% hydrogen peroxide pretreatment before each UVA irradiation during maintenance exposure
Number of subjects: 0
Study 1967882 — intervention group
Group type: COMPARATOR
Intervention: UVA exposure alone after finishing hydrogen peroxide pretreatment
Number of subjects: 0
Study 6160324 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pindolol (0.4 mg)
Number of subjects: 20
Study 6160324 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pindolol (5 mg, t.i.d.)
Number of subjects: 20
Study 6160324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31784852 — intervention group
Group type: EXPERIMENTAL
Intervention: HPI (n=25)
Number of subjects: 99
Study 31784852 — intervention group
Group type: COMPARATOR
Intervention: CTRL (n=24)
Number of subjects: 99
Study 31784852 — intervention group
Group type: COMPARATOR
Intervention: hCTRL (n=50)
Number of subjects: 99
Study 30680547 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12-fortified toothpaste (100 µg cyanocobalamin/g)
Number of subjects: 92
Study 30680547 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 92
Study 28697211 — intervention group
Group type: EXPERIMENTAL
Intervention: Cement-retained (CR) crowns
Number of subjects: 51
Study 28697211 — intervention group
Group type: COMPARATOR
Intervention: Screw-retained (SR) crowns
Number of subjects: 51
Study 25887747 — intervention group
Group type: EXPERIMENTAL
Intervention: GP-led telephone triage
Number of subjects: 44
Study 25887747 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led telephone triage
Number of subjects: 44
Study 25887747 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 44
Study 23318812 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (30 ml bolus at 2.5 mg/ml followed by continuous infusion at 5 ml/h for 48 hours)
Number of subjects: 50
Study 23318812 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline, same administration as bupivacaine)
Number of subjects: 50
Study 23318812 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 50
Study 21111685 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (8 sessions over 4 weeks)
Number of subjects: 77
Study 21111685 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 20 mg daily for 2 weeks followed by 10 mg daily for 2 weeks (n = 39)
Number of subjects: 77
Study 19505986 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting β-agonist (LABA) with mandatory inhaled corticosteroid (ICS) therapy
Number of subjects: 60954
Study 16760520 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 200 mg three times a day
Number of subjects: 399
Study 16760520 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg two times a day
Number of subjects: 399
Study 16760520 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times a day
Number of subjects: 399
Study 15065973 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback with varying specificity
Number of subjects: 0
Study 11375342 — intervention group
Group type: EXPERIMENTAL
Intervention: KPT‐S
Number of subjects: 31
Study 11375342 — intervention group
Group type: EXPERIMENTAL
Intervention: KPT‐P
Number of subjects: 31
Study 11375342 — intervention group
Group type: EXPERIMENTAL
Intervention: KPT‐S and KPT‐P
Number of subjects: 31